TORONTO , Nov. 18, 2022 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMXC), the global leader in medical cannabis throughout Latin America and Europe , today announces that it will host a Conference Call on November 30, 2022 at 11:00 a.m. eastern time to discuss its results for the third quarter ended September 30, 2022 . The Company will press release its... Read More

Through its newly acquired EU-GMP distribution hub in Germany , Khiron expands its product portfolio and geographic reach within Europe to Germany , UK, and Switzerland . Switzerland : Khiron enters the Swiss medical cannabis market with the first sales of two of its new flower products, namely the KHIRON Gelato 19/1 and the first THC:CBD balanced flower product KHIRON Caramel 5/7 UK: Marking the 1 st year anniversary of... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a global leader in medical cannabis throughout Europe and Latin America , today announced that received the Best Latin American Cannabis Company award at Benzinga's 2022 Cannabis Capital Conference in Chicago . "This award recognizes our efforts and achievements as a Latin American Company that radiates throughout our... Read More

New products to be distributed through Khiron's new wholly-owned subsidiary Pharmadrug Production GmbH Khiron introduces new THC-dominant full-spectrum extract KHIRIOX 25/1, and non-irradiated flower varieties KHIRON Gelato 19/1 and KHIRON Caramel 5/7 in the European market Khiron's expanded medical product portfolio in Europe will provide a broader patient base with in-demand products Khiron Life Sciences Corp. ("Khiron" or... Read More

Reports revenues of $9.1 million in the first half of 2022, up 62% year-over-year, reflecting continued medical cannabis momentum in target markets Recorded its lowest ever Adjusted EBITDA loss in Q2 2022 at ($2.3) million , down 30% quarter-over-quarter and 39% year-over-year Net loss of ($2.2) million for Q2 2022 represents a 60% decrease quarter-over-quarter and 55% year-over-year Net cash used in operating activities in... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)( Frankfurt : A2JMXC), the global leader in medical cannabis throughout Latin America and Europe , today announces that it will host a Conference Call on Monday, August 29, 2022 at 10:00 a.m. eastern time to discuss its results for the second quarter ended June 30, 2022 . The Company will press release its financial results prior to the... Read More

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (FSE: A2JMZC) ("Khiron" or the "Company"), a global leader in medical cannabis throughout Europe and Latin America, today announced that Alvaro Torres, CEO and Director of the Company will be attending the Q3 Virtual Investor Summit. Event: Q3 Investor Summit Date: August 16 & 17th, 2022 Presentation: August 17 @ 9:30am ET Location:... Read More

Continued Global Growth of Khiron's Proven Zerenia TM Clinic Model Focused on Patients, Physician Education and Innovation New clinic is in the district of Ipanema in Rio de Janeiro , a city with more than 12 million people Expansion into Brazil follows Khiron´s proven and unique patient acquisition and retention model 40% of... Read More

Acquisition provides Khiron with an EU-GMP European manufacturing and distribution hub for medical cannabis and other pharmaceutical products The acquisition of Pharmadrug Production GmbH provides Khiron with direct access to German pharmacies and increase in gross margins for its products With acquisition completed, Khiron will continue sales of its current products and expand its portfolio, expecting higher gross margins... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a global leader in medical cannabis throughout Latin America and Europe , today announced that Helen Bellwood (ACA) will be appointed as Interim CFO, replacing Swapan Kakumanu of RTB LLP, effective immediately. Prior to her appointment as Interim CFO, Ms. Bellwood was acting as Head of Finance for Khiron´s European... Read More

Khiron's Medical Clinics and Distribution Growth Throughout Europe Follows Success in Latin American Marketplace Since establishing a Spanish subsidiary in 2019, Khiron's scientific and medical team is recognized as cannabinoid experts in Spain Khiron continues its long-standing relationship with the Spanish Agency of Medicines and Medical Devices (AEMPS) and actively contributes to several educational initiatives in Spain... Read More

Khiron Serves Record Number of Patients With Khiron Products Globally in Its Medical Treatment Clinics Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC) the global medical cannabis leader, continues expansion of the Khiron end-to-end solution throughout Latin America and Europe . Khiron's growth aligns with its mission to improve consumers' quality of life through its global network of medical... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a global leader in medical cannabis throughout Latin America and Europe , announces the results of its 2022 Annual General and Special Meeting of shareholders (the "Meeting") held on June 23, 2022 . Shareholders approved all of the resolutions detailed in the management information circular of the Company dated May 17,... Read More

Khiron Life Sciences Corp. (" Khiron " or, the " Company ") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), is pleased to announce that it has closed today its previously announced underwritten overnight public offering of units of the Company (" Units "), including the exercise in full of the over- allotment option (the " Offering "). A total of 30,705,000 Units were sold at a price of $0.15 per Unit (the " Issue Price... Read More

Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has priced and sized its previously announced underwritten overnight marketed public offering (the " Offering "). Pursuant to the Offering, the Company will issue 26,700,000 units of the Company (each, a " Unit ") at a price of C$0.15 per Unit (the " Offering Price ") for aggregate gross proceeds of... Read More

Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has launched an underwritten overnight public offering (the " Offering ") of the Company's units (each, an " Unit "). Each Unit will consist of one common share of the Company (each, a " Unit Share ") and one Common Share purchase warrant of the Company (each, a " Unit Warrant "), with each Unit Warrant being... Read More

The acquisition will accelerate Khiron's growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies The acquisition will provide Khiron with an EU GMP-certified European manufacturing and distribution hub for various pharmaceutical products The target is an experienced player in the European pharmaceutical market, and the acquisition will help to significantly... Read More

The Corporation recorded revenues of $4.6 million in Q1 2022, a 65% increase from Q1 2021, and a 28% increase from Q4 2021 Record revenue in medical cannabis of over $2.6 million in Q1 2022, a 470% increase from the prior year and 32% increase from Q4 2021 Gross profit before fair value adjustments grew to $2.1 million , up 96% from Q1 2021, driven primarily by its 75% gross margin medical cannabis business, compared to 49%... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMXC), the global medical cannabis leader expanding throughout Latin America and Europe , today announces that it will host a Conference Call on Tuesday, May 31, 2022 at 10:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2022 . The Company will press release its financial results prior to the... Read More

In Q1 2022, Khiron expects to surpass 1 million CAD in medical cannabis revenues in the United Kingdom ("UK") alone Total untapped potential for cannabis patients in the UK exceeds 1M patients Supported by its clinic in the UK opened in late 2021, Khiron has increased its sales volumes more than 240% in Q1 2022 compared to entire 2021 Khiron's growing portfolio in the UK includes KHIRON 20/1, one of the best-selling... Read More

2021 total revenue increased over 60% YoY to $12.8 million compared to the previous year Corporation's medical cannabis sales in 2021 increased to $4.6 million , representing 36% of total revenue The Corporation forecasts Q1 2022 sales revenue of ~ $4.5 million for the quarter Gross profit increased over 230% YoY to $4.9... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)( Frankfurt : A2JMZC), the global medical cannabis leader expanding throughout Latin America and Europe , today announces that it will host a conference call on Monday, May 2 nd , 2022 at 10:00 a.m. Eastern Time to discuss its financial results for year ended and quarter ended December 31, 2021 . The Company will press release its financial... Read More

Continues market leadership in Colombia , Latin America's only country with universal health coverage for medical cannabis Market leader in the Colombian medical cannabis market, with Q1 2022 volume sales exceeding 21,400 units , up 280% YoY and more than 40% of all 2021 New clinic continues Khiron's unique patient acquisition... Read More

Data Substantiates Company's Position as a Global Leader In Health Care Solutions Key findings in the study include: 9 out of 10 patients reported some degree of improvement of their chronic pain. 7 out of 10 reported an improvement larger than 50% after 4 weeks of treatment. 7 out of 10 patients did not experience any adverse... Read More

Teleton has 24 Medical Centers (22 rehabilitation centers, 1 autism center and 1 Children's Hospital for Cancer) located across the country, and around 600,000 patients with disability, cancer and autism conditions The partnership includes: Establishment of Khiron's Zerenia™ medical cannabis clinics within Teleton's network... Read More

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the March 10 th Life Sciences Investor Forum are now available for on-demand viewing. REGISTER OR LOGIN NOW AT: https://bit.ly/3hVNWhL The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s resource section.... Read More

NEW YORK, March 08, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10 th . This virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. Individual investors, institutional investors, advisors, and analysts are invited to... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)( Frankfurt : A2JMZC), a medical cannabis leader with core operations in Latin America and Europe , is scheduled to participate in the following virtual and in-person conferences in March 2022 : Q1 2022 VIRTUAL INVESTOR SUMMIT March 8 -10 , 2022 Khiron Presentation: Tuesday, March 8 th at 9:30 a.m. ET Webcast:... Read More

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Investor Forum on March 10 th . This virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT:... Read More

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (OTCQX:KHRNF) (TSX-V:KHRN) (Frankfurt:A2JMZC), a medical cannabis leader with core operations in Latin America and Europe, today announced that Alvaro Torres, CEO and Director, will present live at www.VirtualInvestorConferences.com on March 10th, 2022. DATE: March 10th, 2022 TIME: 11:30AM ET LINK: https://bit.ly/3KiMjGY This will be a live, interactive online event... Read More

Khiron Life Sciences Corp. (TSXV: KHRN.V) today announced that Alvaro Torres will be attending the Q1 Virtual Investor Summit. Mr. Torres is the founder, CEO and Director of Khiron. He has almost two decades of experience in the Latin American market, including infrastructure projects and project finance, management strategy, team development, and mergers and acquisitions. Mr. Torres was previously head of business... Read More

Khiron partners with specialized pain clinic, Clínica del Dolor Lima ("CDL") to provide medical cannabis treatment access to its over 10,000 chronic pain patient population Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a global medical cannabis leader with core... Read More

Starting January 1st, 2022 , every insurance provider in Colombia , is now mandated to cover the costs of high and low THC medical cannabis prescriptions Significantly improves the current insurance coverage process, simplifying the procedure and reducing approval times for patients to obtain insurance coverage across the... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced today its CEO, Alvaro Torres will be participating in the Lytham Partners Winter 2021 Investor Conference taking place... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe , announces the award of stock options ("Options") and restricted share units ("RSUs") under the Company's amended and restated... Read More

Q3 2021 revenue increased 83% YoY to $3.5 million compared to the previous year Gross profit before changes in FV in Q3 2021 increased 62% sequentially to $1.7 million Medical cannabis revenues increased 46% sequentially to $1.2 million Continued strong gross margins for medical cannabis segment at 89% Khiron Life Sciences... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)( Frankfurt : A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe , today announces that it will host a conference call on Monday, November 22 nd , 2021 at 10:00 a.m. Eastern Time to discuss... Read More

Khiron Life Sciences Corp. (TSXV: KHRN) today announced that Alvaro Torres, CEO will be attending the Q4 Virtual Investor Summit. Event Q4 Investor Summit Date November 16-17th, 2021 Presentation November 16th at 11:45 AM ET Location https://us06web.zoom.us/webinar/register/WN_PF7iJRaJQgyHbM9Z-yNkxA About Khiron Life Sciences Corp. Khiron is a leading vertically integrated international medical cannabis company with core... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe , is scheduled to participate in the following virtual and in-person conferences in November 2021 : CANNABIS EUROPA Banking Hall,... Read More

Zerenia™ Clinics UK is a specialist medical cannabis clinic in London and another strategic approach by Khiron to improve access to medical cannabis for patients in the UK Hybrid clinic model: Zerenia™ Clinics UK is a digital clinic ( www.zereniaclinic.co.uk ) and will also offer in-person appointments with medical cannabis... Read More

Khiron Life Sciences Corp. (TSXV: KHRN.V) (OTCQX: KHRNF) (FSE: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, will be participating in the Benzinga Cannabis Capital Conference , which will take place on October 14 and October 15 at the Marriott Marquis hotel in New York City . Virtual access to the conference for those unable to attend in person is also available. Alvaro... Read More

12-month observational study results presented at the International Pain Conference in Colombia on September 25 th , 2021 1 st research study of its kind with a significant patient base for medical cannabis in LatAm 1,453 patients in 12-month period, serviced at Khiron's Zerenia clinics in Colombia , using Khiron's CBD and THC... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe , is scheduled to participate in the following virtual investor conferences in October 2021 : A.G.P.' S VIRTUAL FALL CONSUMER... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)( Frankfurt : A2JMZC), a vertically integrated international cannabis leader with core operations in Latin America and Europe , is pleased to provide a corporate update on global medical cannabis operations: Medical Cannabis Latin America Medical... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)( Frankfurt : A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe , today announced that Joel Friedman , has resigned as Chief Financial Officer of the Company for personal reasons. Khiron's... Read More

Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN), (OTCQB: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America , is pleased to announce that, further to its September 9, 2021 press release, the Company has received final approval from the TSX Venture Exchange (the " TSXV ") to renew its normal course issuer bid to repurchase, for cancellation, up... Read More

Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN), (OTCQX: KHRNF) , ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe , announces today its intention to renew its prior normal course issuer bid through the facilities of the TSX Venture Exchange... Read More

Alixen™ 30 and Alixen™ 100, CBD-rich products, become Khiron's first two registered medical cannabis products, following approval by the Peruvian sanitary agency, DIGEMID Shelf-ready Alixen™ 30 and Alixen™ 100, exported from Colombia , to be broadly distributed throughout pharmacy chains, medical distributors, and dispensaries in Peru starting Q4 2021 Product availability expected to improve service levels for new and... Read More

Q2 2021 revenues of $2.8 million , up 68% YoY Medical cannabis revenues reach $825,500 , up 47% sequentially, with sales in Colombia , Germany , UK, and Peru contributing to gross medical cannabis profit margin of 88% European medical cannabis sales growth of 280% sequentially, representing over 25% of total medical cannabis revenues Medical cannabis expected to become dominant revenue stream, with monthly revenues forecast... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)( Frankfurt : A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe , today announces that it will host a conference call on Monday, August 23 rd , 2021 at 10:00 a.m. Eastern Time to discuss its... Read More

Khiron Life Sciences Corp. (TSXV: KHRN) today announced that Alvaro Torres will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 17th at 10:15 ET Location https://zoom.us/webinar/register/WN_B3t_FX5BTbSU28vXaAEXHg About Khiron Life Sciences Corp. Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe , is pleased to announce the release of its inaugural Environmental, Social and Governance (ESG) report, which captures the period between January 1, 2020 and December 31, 2020 . Showcasing the Company's commitment to... Read More

In 2013, Dr. Faveret became one of the first Brazilian physicians to prescribe medical cannabis, subsequently treating more than 3,000 patients with various conditions across the country As Medical Director for Zerenia™, Dr. Faveret will lead patient prescriptions, physician outreach and education, and data-driven product development for Khiron in Brazil , leveraging relationships and deep medical cannabis expertise... Read More

On July 23, 2021 , the Colombian Government signed Decree 811 of 2021, expanding the regulatory framework for domestic and export medical cannabis markets in Colombia With the Decree, Colombia continues to serve as a regulatory leader and reference point for other countries in the region, having also approved universal... Read More

Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN) (OTCQX: KHRNF) is pleased to announce that it has closed its offering to U.S. institutional investors of 27,435,000 units of the Company (the " Offered Units "), at a price of $0.45 per Offered Unit, for aggregate gross proceeds to the Company of $12,345,750 , as previously announced on July 5, 2021 and July 6, 2021 (the " Offering "). Alvaro Torres ,... Read More

Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN) (OTCQX: KHRNF), is pleased to announce that, in connection with its previously announced overnight marketed offering, A.G.P./Alliance Global Partners ("AGP") (the "Placement Agent" or "AGP") has agreed to sell 27,435,000 units ("Units") of the Company at a price of $0.45 per Unit for gross proceeds of $12,345,750 (the "Offering"). ATB Capital Markets... Read More

Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN) (OTCQX: KHRNF) announces that it has commenced an overnight marketed offering (the " Offering ") of the Company's units (each an " Offered Unit ") on a reasonable best-efforts agency basis, with each Offered Unit comprising of one common share and one common share purchase warrant (each a " Warrant ") at a price of $0.45 per Offered Unit. Each Warrant... Read More

Lytham Partners to Provide Investor Relations Services Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe , announces the results of its 2021 Annual General Meeting of... Read More

With over 200 million people, Brazil is Latin America´s largest addressable medical cannabis market, with the potential to reach USD$1.4 billion in annual revenue (Source: New Frontier Data) In partnership with leading medical cannabis patient association in Brazil , a child with epilepsy becomes first Brazilian patient to receive Khiron medical cannabis product Khiron plans to expand Zerenia™ vertically integrated clinic... Read More

Mexico's Supreme Court has voted to decriminalize adult use cannabis, allowing adults to apply for permits to cultivate and consume their own cannabis Khiron reiterates plans to enter Mexican medical cannabis market in 2021 through previously announced clinic and education strategy Recent regulatory and supply chain advances... Read More

With a population close to 130 million people, Mexico is among the top 15 economies worldwide and second largest in Latin America . Approximately 11.7 million people have conditions treatable with medical cannabis (Source: IMS Quintiles) Leveraging its Project of National Strategic Interest (PINES) designation, Khiron receives THC extract export quota for Mexico from Colombia , for up to 700 Kg of extract and finished... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe , is pleased to announce the appointment of Franziska Katterbach as President, Khiron Europe to replace Tejinder Virk , who... Read More

Company launches first Zerenia™ medical cannabis clinic outside of Colombia , exporting proven clinic model via strategic partnership with Lima -based Clinica Montesur Clinica Montesur is a specialized medical clinic with over 90 doctors covering 19 specialties and 11,000 patient transactions annually; its clinic is centrally located in Lima, Peru , a city of 10 million people or a third of the country's total population... Read More

Khiron's largest shipment to date of EU-GMP certified medical cannabis product arrives in Germany Khiron 20/1, a THC-dominant Cannabis flower, becomes second Khiron-branded product to launch in Germany , having been prescribed in the UK 36.6kg shipment expected to have positive impact on Q2 2021 medical cannabis sales in Europe German medical cannabis market positioned for significant growth with national insurance coverage... Read More

Khiron Life Sciences Corp. (TSXV: KHRN) will be presenting at the Benzinga Cannabis Capital Conference taking place on June 3-4, 2021. We invite our shareholder and all interested parties to join us for a full day of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: https://events.benzinga.com/ccc-free-registration About Benzinga Cannabis Capital Conference Benzinga's virtual Cannabis... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe , is pleased to announce that the Company´s management will be participating in the following investor: Jefferies Healthcare Conference Date: June 2 nd , 2021 Time: 4:00pm ET To register:... Read More

Record revenues of $2.8 million in Q1 2021, a 49% increase from the prior year and 13% increase from Q4 2020 Record gross profits (before fair market value adjustments) of $1.1 million , a 171% improvement over Q4 2020 and record consolidated gross margin of 38% Medical cannabis sales reach 20% of revenues, contributing over 45% of gross profits More than 7,500 prescriptions filled in Q1 2021 and over 19,000 to date First... Read More

Khiron and the Colombia Cancer League, together with 21 leading medical institutions in 11 cities throughout Colombia , have co-launched the "Cannabis: Medicine for Your Life" campaign which aims to improve safe access to consultations for medical cannabis Physicians participating in the campaign will donate more than 3,000 consultations, initially available to chronic pain, palliative care and oncology patients As the... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe , today announces that it will host a conference call on Friday, May 28, 2021 at 10:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2021 . The Company will provide its financial results in a... Read More

Khiron Life Sciences Corp. (TSXV: KHRN) today announced that Alvaro Torres will be attending the Q2 Virtual Investor Summit. Event Q2 Investor Summit Date May 17-18th, 2021 Presentation May 18th at 1:15 PM ET Location https://zoom.us/webinar/register/WN_j9QFPydER8qiLMffjsCgFA About Khiron Life Sciences Corp. Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and... Read More

Khiron is a founding member of Project Twenty 21 and was the first supplier of EU-GMP high-THC dried cannabis flower to the study The findings show that medical Cannabis dramatically improves quality of life for people with life-limiting conditions, including Chronic Pain, Multiple Sclerosis, Tourette's Syndrome and PTSD Legal prescriptions allow patients to access medical cannabis without engaging in criminality and to... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe , is pleased to announce that Chairman Chris Naprawa will present live at Canaccord Genuity's 2021 Virtual Cannabis Conference on... Read More

Generated 31% sequential quarter-on-quarter growth in Q4 2020, driven by normalized clinic operations and more than doubling of medical cannabis sales. Benefited from medical cannabis insurance coverage in Colombia effective December 2020 . Insurance coverage continues to be a catalyst for growth in Colombia , with more than 7,500 prescriptions filled in Q1 2021 versus over 3,300 in Q4 2020. Maintained strong domestic... Read More

Company has received UK Continuing Professional Development ("CPD") accreditation for its global education platform, Khiron Academy UK medical professionals may now earn CPD credits through Khiron's medical cannabis education program The Company has entered into a strategic partnership with Cellen Therapeutics, a leader in... Read More

Following successful medical cannabis launch in Germany , Khiron 1/14, a high CBD flower is expected to be available in Q2/21 for UK patients Khiron plans to introduce additional cannabis-based medical products with its registered strains, recently exported from Colombia to Europe Supply chain improvements will increase... Read More

First shipment of Khiron branded EU-GMP certified medical cannabis to Germany successfully completed, providing immediate access to German market through distribution partner, Nimbus Health GmbH Launch product is Khiron 1/14 high-CBD flower, which will focus on indications such as anxiety, substance use disorder, and... Read More

Zerenia™ expansion follows successful start to 2021, with paid prescriptions in first 2.5 months of the year exceeding total 2020 prescriptions in Colombia Satellite clinics proving an effective patient acquisition model; in first two months of 2021, a significant number of new paying patients were acquired through Khiron's... Read More

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announced that Alvaro Torres, CEO, will be attending the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March 23-25th, 2021 Presentation March 24th @ 1:00PM ET Location https://zoom.us/webinar/register/WN_t9RgOzoRRWWAbgaCyaYTaQ About The... Read More

Khiron has successfully exported its registered cannabis strains, in the form of live clones, from Colombia to Europe Company is executing on an asset light growth strategy in Europe by working with contract manufacturing and distribution partners to accelerate production and delivery of EU-GMP certified medical cannabis... Read More

International Diploma in Medicinal Cannabis for Latin American doctors to be hosted virtually through Mexico's TecSalud School of Medicine and Health Sciences (EMCS), beginning February 20, 2021 Physicians from Mexico and across Latin America will participate in a fee-based 6-week diploma program Diploma marks a historic advance in medical education around the prescription of medicinal cannabis in Mexico and the Latin... Read More

Khiron Life Sciences Corp. (TSXV: KHRN) will be presenting at the Benzinga Cannabis Capital Conference taking place on February 25-26, 2021. We invite our shareholder and all interested parties to join us for a full day of networking, dealmaking and discovery. Sign up to get a free spectator pass for the event: https://events.benzinga.com/ccc-free-registration. About Benzinga Cannabis Capital Conference Benzinga's virtual... Read More

Khiron to launch two additional small-format Zerenia™ clinics in major metropolitan centres outside of Bogota in early March 2021 , following successful launch of the Company's first small-format clinic in Medellin in December 2020 New clinics bring Khiron's total number of clinics in Colombia to six, expanding regional access throughout the country, where an estimated 6 million people have conditions that may be treated... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe , announces the award of restricted share units ("RSUs") under the Company's amended and restated restricted share unit plan approved by shareholders at the annual general and special meeting of shareholders held on September 10,... Read More

Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe , is pleased to announce that Alvaro Torres , Khiron CEO and director, along with members of the Khiron management team, will host a live webcast on Wednesday, February 17 at 11:00am ET to discuss recent results and management's... Read More